Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44255   clinical trials with a EudraCT protocol, of which   7344   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2019-001346-17
    Sponsor's Protocol Code Number:ALN-GO1-005
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Trial now transitioned
    Date on which this record was first entered in the EudraCT database:2021-06-07
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2019-001346-17
    A.3Full title of the trial
    ILLUMINATE-C: A Single Arm Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1 (PH1)
    ILLUMINATE-C: Studio a braccio singolo volto a valutare l'efficacia, la sicurezza d'uso, la farmacocinetica e la farmacodinamica di lumasiran nei pazienti affetti da iperossaluria primitiva di tipo 1 (HP1) in fase avanzata
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A Phase 3 study of an Investigational Drug, Lumasiran (ALN-GO1) in patients with advanced primary hyperoxaluria Type 1
    Studio di fase 3 di un farmaco sperimentale, Lumasiran (ALN-GO1) in pazienti con iperossaluria primitiva di tipo 1 in fase avanzata
    A.3.2Name or abbreviated title of the trial where available
    ILLUMINATE-C
    ILLUMINATE-C
    A.4.1Sponsor's protocol code numberALN-GO1-005
    A.7Trial is part of a Paediatric Investigation Plan Yes
    A.8EMA Decision number of Paediatric Investigation PlanP/373/2017
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorALNYLAM PHARMACEUTICALS, INC.
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportAlnylam Pharmaceuticals, Inc.
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationAlnylam Pharmaceuticals, Inc.
    B.5.2Functional name of contact pointClinical Trial Information Line
    B.5.3 Address:
    B.5.3.1Street Address300 Third Street
    B.5.3.2Town/ cityCambrigde, Massachusetts
    B.5.3.3Post code02142
    B.5.3.4CountryUnited States
    B.5.4Telephone number0018772569526
    B.5.5Fax number0018772569526
    B.5.6E-mailclinicaltrials@alnylam.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community Yes
    D.2.5.1Orphan drug designation numberEU/3/16/1637
    D.3 Description of the IMP
    D.3.1Product namelumasiran
    D.3.2Product code [ALN-GO1]
    D.3.4Pharmaceutical form Solution for injection/infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPSubcutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNLumasiran
    D.3.9.2Current sponsor codeALN-GO1
    D.3.9.4EV Substance CodeSUB194008
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number189
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Primary Hyperoxaluria Type 1 (PH1)
    iperossaluria primitiva di tipo 1 (HP1)
    E.1.1.1Medical condition in easily understood language
    A rare genetic metabolic disorder leading to kidney stones and / or excess calcium deposition in the kidneys, eventually resulting in kidney failure.
    Un raro disturbo metabolico genetico che porta alla formazione di calcoli renali e/o alla deposizione di calcio in eccesso nei reni, con possibile conseguente insufficienza renale.
    E.1.1.2Therapeutic area Diseases [C] - Nutritional and Metabolic Diseases [C18]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.1
    E.1.2Level PT
    E.1.2Classification code 10020703
    E.1.2Term Hyperoxaluria
    E.1.2System Organ Class 10038359 - Renal and urinary disorders
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    Cohort A
    • Evaluate the effect of lumasiran on plasma oxalate in patients who are not on dialysis therapy
    Cohort B
    • Evaluate the effect of lumasiran on plasma oxalate levels in patients who are on dialysis therapy
    Coorte A
    • Valutare l’effetto di lumasiran sull’ossalato plasmatico in pazienti non in trattamento dialitico
    Coorte B
    • Valutare l’effetto di lumasiran sui livelli plasmatici di ossalato in pazienti in trattamento dialitico
    E.2.2Secondary objectives of the trial
    • Evaluate the effect of lumasiran on change in plasma oxalate area under the curve (AUC) between dialysis sessions
    • Evaluate the long-term effects of lumasiran on change in plasma oxalate
    • Evaluate the effect of lumasiran on change in urinary oxalate excretion
    • Evaluate quality of life in patients with PH1
    • Characterize the PK of lumasiran
    • Evaluate the effect of lumasiran on nephrocalcinosis
    • Evaluate the effect of lumasiran on dialysis requirements
    • Evaluate the effect of lumasiran on the occurrence of renal stones
    • Evaluate the effect of lumasiran on renal function
    • Evaluate the effect of lumasiran on change in measures of systemic oxalosis
    • Valutare l’effetto di lumasiran sulla variazione nell’area sotto la curva (AUC) dell’ossalato plasmatico tra le sessioni dialitiche
    • Valutare gli effetti a lungo termine di lumasiran sulla variazione dell’ossalato plasmatico
    • Valutare l’effetto di lumasiran sulla variazione nell’escrezione di ossalato urinario
    • Valutare la qualità di vita nei pazienti con HP1
    • Caratterizzare la farmacocinetica (PK) di lumasiran
    • Valutare l’effetto di lumasiran sulla nefrocalcinosi
    • Valutare l’effetto di lumasiran sulla necessità di dialisi
    • Valutare l’effetto di lumasiran sull’insorgenza di calcolosi renali
    • Valutare l’effetto di lumasiran sulla funzione renale
    • Valutare l’effetto di lumasiran sulla variazione nelle misure dell’ossalosi sistemica
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    Cohorts A and B
    1. Have reached at least 37 weeks estimated gestational age (full-term infant) at consent (or assent).
    2. Documentation or confirmation of PH1 as determined by genetic analysis prior to initial dosing.
    3. Patients with eGFR <=45 mL/min/1.73 m2 as calculated by the MDRD formula if >=18 years or Schwartz Bedside Formula if >=12 months to <18 years, or patients <12 months of age with serum creatinine that is considered elevated for age at consent.
    4. The mean of the three most recent screening plasma oxalate samples collected prior to Day 1 is >=20 µmol/L. In Cohort B, these 3 collections may include the first pre-dialysis sample from each plasma oxalate profile.
    5. If taking therapeutic vitamin B6 (pyridoxine), must have been on stable regimen for at least 90 days before consent, and is able and willing to remain on this stable regimen until at least the Month 6 visit. Dose adjustments for interval weight gain are acceptable.
    6. Patient is willing and able to comply with the study requirements and to provide written informed consent. In the case of patients under the age of legal consent, the legal guardian(s) must provide informed consent and the patient should provide assent per local and national requirements.
    Cohort B Only
    1. On a stable hemodialysis regimen for at least 4 weeks prior to Screening plasma oxalate assessment; able and willing to maintain this regimen through Month 6 visit, with changes to dialysis regimen permitted only when medically indicated.
    Coorte A e B
    1. Aver raggiunto almeno 37 settimane di età gestazionale stimata (neonato a termine) al momento del consenso (o dell'assenso).
    2. Documentazione o conferma del HP1 come determinato dall'analisi genetica prima del dosaggio iniziale.
    3. Pazienti con eGFR <=45 mL/min/1,73 m2 come calcolato dalla formula MDRD se >=18 anni o dalla Schwartz Bedside Formula se >=12 mesi a <18 anni, o pazienti <12 mesi di età con creatinina sierica considerata elevata per l'età al consenso.
    4. La media dei tre più recenti campioni di plasma ossalato di screening raccolti prima del 1° giorno è >=20 µmol/L. Nella Coorte B, queste 3 raccolte possono includere il primo campione di pre-dialisi di ogni profilo di plasma ossalato.
    5. Se si assume la vitamina B6 terapeutica (piridossina), deve essere stato in regime stabile per almeno 90 giorni prima del consenso, ed è in grado e disposto a rimanere su questo regime stabile fino almeno la visita a 6 mesi. Sono accettabili aggiustamenti della dose per aumento di peso ad intervalli di tempo.
    6. Il paziente è disposto e in grado di soddisfare i requisiti dello studio e di fornire il consenso informato per iscritto. Nel caso di pazienti al di sotto dell'età del consenso legale, il tutore legale deve fornire il consenso informato e il paziente deve fornire l'assenso secondo i requisiti locali e nazionali.

    Solo Coorte B
    1. In un regime di emodialisi stabile per almeno 4 settimane prima dello screening della valutazione dell'ossalato plasmatico; in grado e disposto a mantenere questo regime fino alla visita del mese 6, con modifiche al regime di dialisi consentite solo quando indicato dal medico.
    E.4Principal exclusion criteria
    1. Has any of the following laboratory parameter assessments at Screening:
    a. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2× ULN for age
    b. Total bilirubin >1.5×ULN. Patients with elevated total bilirubin that is secondary to documented Gilbert's syndrome are eligible if the total bilirubin is <2× ULN
    c. International normalized ratio (INR) >1.5 for patients not on anticoagulants. Patients on oral anticoagulants (eg, warfarin) with an INR <3.5 will be allowed.
    d. Hemoglobin <8.0 dL
    2. Has known active human immunodeficiency virus (HIV) infection; or evidence of current or chronic hepatitis C virus (HCV) or hepatitis B (HBV) infection.
    3. Received an investigational agent within the last 30 days or 5 halflives, whichever is longer, prior to the first dose of study drug, or are in follow-up of another clinical study during Screening. Consultation with the Medical Monitor is required if treated with unapproved products prior to consent regardless of the time interval prior to the first dose of study drug.
    4. Known history of allergic reaction to an oligonucleotide or GalNAc.
    5. Diagnosis of conditions other than PH1 contributing to renal insufficiency such as glomerulonephritis, nephrotic syndrome, or lupus nephritis.
    6. Any condition or comorbidity, which in the opinion of the Investigator, would make the patient unsuitable for dosing or would interfere with study compliance, data interpretation, patient safety, and/or patient participation in the study. This includes significant active and poorly controlled (unstable) cardiovascular, neurologic, gastrointestinal, endocrine, renal or psychiatric disorders unrelated to PH1 identified by key laboratory abnormalities or medical history.
    7. Unwilling or unable to limit alcohol consumption throughout the course of the study. Alcohol intake of >2 units/day is excluded during the study (unit: 1 glass of wine [approximately 125 mL] = 1 measure of spirits [approximately 1 fluid ounce] = ½ pint of beer [approximately 284 mL].
    8. History of alcohol abuse, within the last 12 months before screening, in the opinion of the investigator.
    9. Patients with a previous liver transplant or for whom a liver transplant is anticipated in the next 6 months.
    10. Patients with a previous kidney transplant who are currently receiving immunosuppression to prevent transplant rejection.
    11. Patients maintained on a peritoneal dialysis regimen.
    12. Patients who in the opinion of the Investigator plan to start dialysis replacement therapy in the next 6 months.
    13. Any comorbidity or condition that, in the opinion of the Investigator, is anticipated to prevent participation in at least 12 months of the study
    14. Is not willing to comply with the contraceptive requirements during the study period, as described in study protocol.
    15. Female patient is pregnant, planning a pregnancy, or breast feeding.
    1. Ha una delle seguenti valutazioni dei parametri di laboratorio allo Screening:
    a. Alanina aminotransferasi (ALT) or aspartato aminotransferasi (AST) >2× ULN per età
    b. Bilirubina totale >1.5×ULN. I pazienti con bilirubina totale elevata che è secondaria a sindrome di Gilbert documentata sono ammissibili se la bilirubina totale è <2× ULN
    c. Rapporto internazionale normalizzato (INR) >1.5 per i pazienti non trattati con anticoagulanti. I pazienti che assumono anticoagulanti per via orale (es. warfarin) con un INR <3.5 saranno ammessi.
    d. Emoglobina <8.0 dL
    2. Ha un'infezione da virus dell'immunodeficienza umana attiva (HIV) nota; oppure evidenza di infezione da virus dell'epatite C (HCV) o da epatite B (HBV) in corso o cronica.
    3. Ha ricevuto un agente sperimentale negli ultimi 30 giorni o 5 emivite, a seconda di quale dei due è più lunga, prima della prima dose di farmaco in studio, o sono in follow-up di un altro studio clinico durante lo Screening. Il consulto con il Medical Monitor è richiesto se trattati con prodotti non approvati prima del consenso, indipendentemente dall'intervallo di tempo prima della prima dose del farmaco in studio.
    4. Storia nota di reazione allergica ad un oligonucleotide o GalNAc.
    5. Diagnosi di condizioni diverse da HP1 che contribuiscono all'insufficienza renale come la glomerulonefrite, la sindrome nefrosica o la nefrite da lupus.
    6. Qualsiasi condizione o comorbilità che, secondo l'opinione dello Sperimentatore, renderebbe il paziente non idoneo al dosaggio o interferirebbe con la compliance allo studio, l'interpretazione dei dati, la sicurezza del paziente e/o la partecipazione del paziente allo studio. Ciò include significativi disturbi attivi e scarsamente controllati (instabili) cardiovascolari, neurologici, gastrointestinali, endocrini, renali o psichiatrici non correlati al HP1 identificati da anomalie importanti di laboratorio o dalla storia medica.
    7. Non disposto o non in grado di limitare il consumo di alcol durante il corso dello studio. L'assunzione di alcolici >2 unità/giorno è esclusa durante lo studio (unità: 1 bicchiere di vino [circa 125 mL] = 1 misura di alcolici [circa 1 oncia fluida] = ½ pinta di birra [circa 284 ml].
    8. Storia di abuso di alcolici, negli ultimi 12 mesi prima dello screening, secondo l'opinione dell'investigatore.
    9. Pazienti con un precedente trapianto di fegato o per i quali è previsto un trapianto di fegato nei prossimi 6 mesi.
    10. Pazienti con un precedente trapianto di rene che attualmente ricevono immunosoppressione per prevenire il rigetto del trapianto.
    11. Pazienti mantenuti in un regime di dialisi peritoneale.
    12. Pazienti che, secondo il parere dell'Investigator plan, prevedono di iniziare una terapia di dialisi sostitutiva nei prossimi 6 mesi.
    13. Qualsiasi comorbilità o condizione che, secondo il parere dell'Investigatore, è destinata ad impedire la partecipazione ad almeno 12 mesi di studio
    14. Non è disposto a rispettare i requisiti contraccettivi durante il periodo di studio, come descritto nel protocollo di studio.
    15. La paziente è incinta, sta pianificando una gravidanza o sta allattando.
    E.5 End points
    E.5.1Primary end point(s)
    Cohort A
    • Percent change in plasma oxalate from Baseline to Month 6
    Cohort B
    • Percent change in pre-dialysis plasma oxalate from Baseline to Month 6
    Coorte A
    • Variazione percentuale di ossalato plasmatico dal basale al Mese 6
    Coorte B
    • Variazione percentuale di ossalato plasmatico pre-dialisi dal basale al Mese 6
    E.5.1.1Timepoint(s) of evaluation of this end point
    6 months
    6 mesi
    E.5.2Secondary end point(s)
    Primary Analysis Period (Baseline to 6 months)
    • Percent change in plasma oxalate AUC between dialysis sessions
    • Absolute change in plasma oxalate
    • Change in the following parameters:
    *Urinary oxalate
    *QoL assessed by the PedsQL Total Score for patients >=2 to <18 years of age at consent, and as assessed by KDQOL Burden of Kidney Disease and Effect of Kidney Disease on Daily Life subscales, and SF-12 Physical
    Component Summary and Mental Component Summary, in patients >=18 years at consent
    • Plasma PK parameters of lumasiran

    Long-term Extension Period (6 months to end of study)
    • Percent change in plasma oxalate AUC between dialysis sessions
    • Percent and absolute change in plasma oxalate
    • Change in the following parameters:
    *Nephrocalcinosis as assessed by renal ultrasound
    *Frequency and mode of dialysis
    *Frequency of renal stone events
    *Urinary oxalate
    *Renal function as assessed by eGFR
    *Measures of systemic oxalosis in the following systems:
    -Cardiac
    -Dermatologic
    -Skeletal
    -Ocular
    *QoL(Quality of life) assessed by the PedsQL Total Score for patients >=2 to <18 years of age at consent, and as assessed by KDQOL Burden of Kidney Disease and Effect of Kidney Disease on Daily Life subscales, and SF-12 Physical Component Summary and Mental Component Summary, in patients >=18 years at consent
    Periodo di analisi primario (dal baseline a 6 mesi)
    • Variazione percentuale nell'AUC dell'ossalato plasmatico tra le sessioni di dialisi
    • Variazione assoluta dell'ossalato plasmatico
    • Variazione nei seguenti parametri:
    * Ossalato Urinario
    * QoL valutato tramite PedsQL Total Score per pazienti >=2 a <18 anni di età al momento del consenso, e valuatata tramite KDQOL Burden of Kidney Disease e sottoscale Effect of Kidney Disease on Daily Life, e tramite SF-12 Physical Component Summary and Mental Component Summary, in pazienti maggiorenni al momento del consenso
    * Parametri PK plasmatici di lumasiran

    Periodo di estensione a lungo termine (da 6 mesi fino alla fine delo studio)
    • Variazione percentuale nell'AUC dell'ossalato plasmatico tra le sessioni di dialisi
    • Variazione percentuale ed assoluta dell'ossalato plasmatico
    • Variazione nei seguenti parametri:
    *Nefrocalcinosi valutata tramite ecografia renale
    * Frequenza e modalità di dialisi
    * Frequenza di calcolosi renale
    • Ossalato urinario
    • Funzione renale misurata tramite eGFR
    • Misurazione di ossalosi plasmatica nei seguenti sistemi:
    - Cardiaco
    - Dermatologico
    - Scheletrico
    - Oculare
    * QoL valutato tramite PedsQL Total Score per pazienti >=2 to <18 anni di età al momento del consenso, e valuatata tramite KDQOL Burden of Kidney Disease e sottoscale Effect of Kidney Disease on Daily Life, e tramite SF-12 Physical Component Summary and Mental Component Summary, in pazienti maggiorenni al momento del consenso
    E.5.2.1Timepoint(s) of evaluation of this end point
    Primary Analysis Period: 6 months
    Long-term Extension Period: 6 months to 5 years
    Periodo di analisi primario: 6 mesi
    Periodo di estensione a lungo termine: da 6 mesi a 5 anni
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other Yes
    E.8.1.7.1Other trial design description
    studio in aperto a braccio singolo
    single arm open study
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial1
    E.8.3 The trial involves single site in the Member State concerned Yes
    E.8.4 The trial involves multiple sites in the Member State concerned No
    E.8.4.1Number of sites anticipated in Member State concerned1
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA6
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Australia
    Egypt
    India
    Israel
    Jordan
    Lebanon
    Turkey
    United Arab Emirates
    United States
    Belgium
    France
    Germany
    Netherlands
    Switzerland
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years5
    E.8.9.1In the Member State concerned months0
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years5
    E.8.9.2In all countries concerned by the trial months0
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 Yes
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) Yes
    F.1.1.4.1Number of subjects for this age range: 2
    F.1.1.5Children (2-11years) Yes
    F.1.1.5.1Number of subjects for this age range: 2
    F.1.1.6Adolescents (12-17 years) Yes
    F.1.1.6.1Number of subjects for this age range: 2
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 14
    F.1.3Elderly (>=65 years) No
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally Yes
    F.3.3.6.1Details of subjects incapable of giving consent
    In the case of patients under the age of legal consent, the legal guardian(s) must provide informed consent and the patient should provide assent per local and national requirements
    Nel caso di pazienti minorenni, i tutori legali devono fornire il consenso informato e il paziente dovrà fornire il suo assenso secondo le normative locali e nazionali
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state1
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 8
    F.4.2.2In the whole clinical trial 20
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Expected Standard of Care
    Secondo l'atteso standard of care
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2021-05-14
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2021-02-24
    P. End of Trial
    P.End of Trial StatusTrial now transitioned
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA